By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



99 Hayden Avenue
Suite 390
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-357-2333 Fax: 781-357-2399



Company News
Pulmatrix Issued Patents Covering iSPERSE Technology For Treatment Of Patients With Inhaled Dry Powders 7/23/2015 8:58:03 AM
Pulmatrix Appoints William Duke, Jr., As Chief Financial Officer 6/25/2015 7:16:45 AM
Pulmatrix Announces Appointment Of Michael Higgins To Board Of Directors 6/18/2015 7:32:53 AM
Pulmatrix Raises $10 Million Private Placement; To Begin Trading On NASDAQ Under "PULM" 6/16/2015 9:10:49 AM
Pulmatrix Announces First Inhaled Anti-fungal Therapy For Cystic Fibrosis 6/16/2015 8:18:25 AM
Pulmatrix And Mylan (MYL) Enter Into Ex-U.S. Development Agreement For PUR0200 6/16/2015 6:12:32 AM
Ruthigen And Pulmatrix Stockholders Approve Merger 6/15/2015 6:40:49 AM
Ruthigen And Pulmatrix Enter Into Merger Agreement 3/16/2015 7:00:36 AM
Pulmatrix Presents Preclinical Data On iSPERSE Inhaled Antibiotics At The 2014 Respiratory Drug Delivery Conference 5/5/2014 9:56:32 AM
Pulmatrix's PUR0200 Demonstrated Encouraging Results In Phase 1B Clinical Study In COPD Patients 5/5/2014 9:52:38 AM